Status checked on October 6, 2026 dailymed.nlm.nih.gov
Mounjaro (tirzepatide) is FDA approved for type 2 diabetes, not weight management: approved uses, how it differs from Zepbound, side effects, boxed warning and savings.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key facts
- Active ingredient
- Tirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro)
- Class
- GIP/GLP-1 dual agonist
- Route
- Injection
- How often
- Weekly
- Manufacturer
- Eli Lilly
- Approved for weight
- No
- First approved
- 2022
- Generic available
- No
- Controlled substance
- No
- Official label
- Prescribing information
Key takeaways
- Mounjaro is FDA approved for type 2 diabetes in adults and children 10 and older, and for cardiovascular risk reduction in high-risk adults with type 2 diabetes; it is not approved for weight management.[1]
- Zepbound contains the same active ingredient, tirzepatide, and is the brand approved for weight management and sleep apnea in adults with obesity.[2]
- In SURPASS-2, tirzepatide lowered HbA1c and weight more than semaglutide 1 mg in adults with type 2 diabetes.[3]
- Nausea, diarrhea and decreased appetite are the most common side effects; Mounjaro carries a boxed warning about thyroid C-cell tumors seen in rats.[1]
Approved uses
Mounjaro (tirzepatide): approved uses and how it differs from Zepbound is FDA approved for Improve glycemic control, as an adjunct to diet and exercise; Improve glycemic control, as an adjunct to diet and exercise; Reduce the risk of major adverse cardiovascular events (CV death, nonfatal heart attack, nonfatal stroke). It is not approved for weight management.
Zepbound (tirzepatide): uses, side effects, cost and FDA status contains the same active ingredient and is approved for chronic weight management.
In short: Mounjaro is tirzepatide approved by the FDA for type 2 diabetes: to improve blood sugar control in adults and in children 10 and older, and to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high cardiovascular risk. It is not approved for weight management. Zepbound contains the same active ingredient and is the tirzepatide brand approved for weight and for sleep apnea in adults with obesity (checked on the FDA label on 2026-10-06).
Mounjaro was the first tirzepatide product and is often discussed for weight. This page explains what it is approved for, how it relates to Zepbound and what the label says about side effects, warnings and cost. It is general information, not medical advice.
What Mounjaro is
Mounjaro is made by Eli Lilly. Its active ingredient, tirzepatide, activates two gut-hormone receptors, GIP and GLP-1, which helps the body release insulin when blood sugar rises, lowers appetite and slows stomach emptying. Our tirzepatide page explains the dual mechanism; the broader class is covered in GLP-1 medications. Mounjaro is a once-weekly injection, available as single-dose pens and vials and as a multi-dose KwikPen.
FDA status and approved uses
According to Drugs@FDA, Mounjaro was first approved on May 13, 2022 to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. On December 19, 2025 the FDA extended the approval to a new patient population: children and teens 10 years and older with type 2 diabetes. On August 27, 2026 a new indication was added: reducing the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in adults with type 2 diabetes who are at high risk of these events.
Mounjaro vs Zepbound
The molecule is the same, but the approvals, the trials behind them and usually the insurance coverage differ. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management in adults with obesity, or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. People with type 2 diabetes in the weight-management trials lost weight on tirzepatide too, but using Mounjaro only for weight would be off-label. Your clinician can explain which product fits the condition being treated.
Who it is labeled for
Adults and pediatric patients 10 years and older with type 2 diabetes for blood sugar control, and adults with type 2 diabetes at high cardiovascular risk for the heart-protection indication. The label sets a lower maximum dose for children than for adults. Mounjaro is not approved for type 1 diabetes or for weight management.
How it is taken, in general
Once a week under the skin, any time of day, with or without meals. The label describes a starting dose for four weeks, followed by step increases at least four weeks apart as needed. As with Zepbound, the label advises people who use birth-control pills to switch to a non-oral method, or add a barrier method, for four weeks after starting and after each dose increase. The prescriber sets the dose and adjusts insulin or sulfonylureas to limit low blood sugar.
What the studies showed
In SURPASS-2 (2021), 1,879 adults with type 2 diabetes took tirzepatide 5, 10 or 15 mg or semaglutide 1 mg weekly for 40 weeks. Tirzepatide lowered HbA1c more than semaglutide 1 mg at every dose, and weight fell more as well (extra differences of 1.9 kg, 3.6 kg and 5.5 kg by dose). In SURPASS-CVOT (2025), 13,165 adults with type 2 diabetes and atherosclerotic cardiovascular disease took tirzepatide or dulaglutide, another GLP-1 medicine. Major cardiovascular events occurred in 12.2% versus 13.1%, which met the test for noninferiority (hazard ratio 0.92) but not for superiority.
Side effects
In the label’s placebo-controlled diabetes trials, nausea was reported by 12% to 18% of people on Mounjaro (4% on placebo), diarrhea by 12% to 17% (9%), decreased appetite by 5% to 11% (1%), vomiting by 5% to 9% (2%), constipation by 6% to 7% (1%), indigestion by 5% to 8% (3%) and abdominal pain by 5% to 6% (4%). Warnings cover acute pancreatitis, low blood sugar with insulin or sulfonylureas, allergic reactions, kidney injury from dehydration, severe digestive reactions, diabetic eye complications, gallbladder disease, aspiration during anesthesia, and never sharing a KwikPen. The class picture is in GLP-1 side effects.
Boxed warning and who should not use it
Mounjaro has a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it does so in humans. It must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2, or with a known serious allergy to tirzepatide.
Cost and savings
Checked on 2026-10-06 on Lilly’s Mounjaro site: with commercial insurance that covers Mounjaro, the savings card can bring a 1-, 2- or 3-month fill to as little as $25. With commercial insurance that does not cover it, the card offers a price as low as $499 for a one-month fill. Government beneficiaries cannot use the card. Medicare’s GLP-1 Bridge is for weight management only and does not include Mounjaro; diabetes treatment goes through regular Part D plans.
Compounded products and related options
Compounded “tirzepatide” is not Mounjaro and has not been reviewed by the FDA for safety, effectiveness or quality; read compounded GLP-1s. For a molecule-level comparison, see semaglutide vs tirzepatide. Other diabetes and weight medicines are on the medications hub, including Ozempic, and nutrition while on these medicines is covered in what to eat on a GLP-1.
FDA status and approved uses
| Indication | Labeled population | For weight | Approved | Source |
|---|---|---|---|---|
| Improve glycemic control, as an adjunct to diet and exercise | Adults with type 2 diabetes mellitus | No | May 13, 2022 | Source |
| Improve glycemic control, as an adjunct to diet and exercise | Pediatric patients 10 years of age and older with type 2 diabetes mellitus | No | December 19, 2025 | Source |
| Reduce the risk of major adverse cardiovascular events (CV death, nonfatal heart attack, nonfatal stroke) | Adults with type 2 diabetes at high risk for these events | No | August 27, 2026 | Source |
From the FDA label. Who a medicine is labeled for is not the same as whether it fits you; only a clinician can decide that.
How it is taken (in general)
Once weekly under the skin, any time of day, with or without meals. The label describes a starting dose for 4 weeks, then increases at least 4 weeks apart as needed, with a lower maximum for children than adults. Follow your prescriber.
This is what the label describes in general, never a personal dose or schedule. Follow your prescriber.
What studies showed
| Trial | Population | Duration | Outcome as reported |
|---|---|---|---|
| SURPASS-2 (vs semaglutide 1 mg) NCT03987919 | 1,879 adults with type 2 diabetes (open label) | 40 weeks | Tirzepatide was noninferior and superior to semaglutide 1 mg for HbA1c; extra weight reduction of 1.9, 3.6 and 5.5 kg at 5, 10 and 15 mg.[3] |
| SURPASS-CVOT (vs dulaglutide) NCT04255433 | 13,165 adults with type 2 diabetes and atherosclerotic cardiovascular disease | Event-driven | Major cardiovascular events 12.2% vs 13.1% (hazard ratio 0.92); noninferior, not superior.[4] |
Average results from trials; individual results vary. Results from different trials cannot be compared directly.
Side effects
| Common side effect | How often (label) |
|---|---|
| Nausea | 12% to 18% (5 to 15 mg) vs 4% placebo |
| Diarrhea | 12% to 17% vs 9% placebo |
| Decreased appetite | 5% to 11% vs 1% placebo |
| Vomiting | 5% to 9% vs 2% placebo |
| Constipation | 6% to 7% vs 1% placebo |
| Dyspepsia (indigestion) | 5% to 8% vs 3% placebo |
| Abdominal pain | 5% to 6% vs 4% placebo |
Serious risks
- Thyroid C-cell tumors (boxed warning, seen in rats)
- Acute pancreatitis
- Hypoglycemia with insulin or insulin secretagogues
- Hypersensitivity reactions
- Acute kidney injury from volume depletion
- Severe gastrointestinal adverse reactions
- Diabetic retinopathy complications
- Acute gallbladder disease
- Pulmonary aspiration during general anesthesia or deep sedation
- Never share a KwikPen between patients
More detail: Mounjaro Side Effects: what the label lists, by dose, and when to get help
Warnings and who should not use it
Boxed warning
Risk of thyroid C-cell tumors: tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Who should not use it (per the label)
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or any of the excipients
Interactions, pregnancy and breastfeeding
| Drug or class | What the label says |
|---|---|
| Oral hormonal contraceptives | Switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase (label). |
| Insulin or sulfonylureas | Higher risk of low blood sugar; the prescriber may lower those doses. |
Pregnancy and breastfeeding
Discuss pregnancy plans and breastfeeding with the prescriber before starting; animal studies of tirzepatide showed harm to the fetus, and the label gives specific advice about contraception during dose increases.
Cost, insurance and savings
| Price | Amount | Basis | Checked on |
|---|---|---|---|
| With savings program | 25 USD | per 1- to 3-month fill with commercial coverage (savings card) | October 6, 2026 |
| With savings program | 499 USD | per 1-month fill with commercial insurance that does not cover Mounjaro (savings card) | October 6, 2026 |
Prices change often and depend on pharmacy, plan and location. Insurance can change what you pay. Every price shows the date we checked it.
Savings programs
- Mounjaro Savings Card: Commercial insurance; government beneficiaries excluded (checked October 6, 2026)
Stopping and keeping results
Trials show that weight often returns after these medicines are stopped. Plan any change with your prescriber. Stopping a GLP-1: what trials show and how people keep results
Compounded and counterfeit versions
Compounded semaglutide and tirzepatide are not FDA approved: the FDA does not review them for safety, quality or effectiveness. Counterfeit pens and "research peptides" sold online have caused harm. Buy only from a licensed pharmacy with a prescription.
Same active ingredient
FDA approved for another usePrescriptionInjectionMounjaro Side Effects: what the label lists, by dose, and when to get helpTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro)
FDA approved for weight managementPrescriptionInjectionZepbound (tirzepatide): uses, side effects, cost and FDA statusTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro) · Injection · Weekly
FDA approved for weight managementPrescriptionInjectionZepbound Side Effects: common, serious and how they compareTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro)Same class
Non-drug approaches
FDA approved for weight managementPrescriptionInjectionZepbound (tirzepatide): uses, side effects, cost and FDA statusTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro) · Injection · Weekly
FDA approved for another usePrescriptionInjectionOzempic (semaglutide): approved uses and how it differs from WegovySemaglutide: one ingredient, several brands · Injection · Weekly
How to Lose Weight: every proven approach in one placeHow to lose weight: the calorie deficit, food, activity, sleep and habits with the best evidence,…
Weight-Loss Diets Compared: evidence, difficulty and costWeight-loss diets compared by evidence, convenience, cost and maintenance: what research says, how to choose, safety,…Cost and coverage
Does Insurance Cover GLP-1s for Weight Loss? (checked quarterly)Does insurance cover GLP-1s for weight loss? Employer data, Medicare rules and the $50 GLP-1 Bridge,…
Mounjaro Cost: self-pay price, savings card and Medicare (prices checked monthly)What Mounjaro costs, with dates: $499 LillyDirect self-pay at every strength, the $25 savings card and…Related guides
GLP-1 Medications: how they work and which are approved for weightGLP-1 medications explained: what GLP-1 is, how the drugs work, which brands are FDA approved for…
GLP-1 Side Effects: common, serious and how they are managedGLP-1 side effects from the FDA labels: common digestive effects by brand, serious risks, the thyroid…
What to Eat on a GLP-1: protein, fiber and handling side effectsWhat to eat on a GLP-1 medicine: protein targets from the 2025 joint advisory, whole-food meals,…Questions to ask your doctor or pharmacist
- Is Mounjaro a good fit for my type 2 diabetes compared with other options?
- If weight is also a goal, how does that change which medicine and which brand is appropriate?
- How should my insulin or sulfonylurea be adjusted if I start Mounjaro?
- What should I do about birth control while the dose is going up?
- What does my plan cover, and would a 3-month fill lower my cost?
Frequently asked questions
Is Mounjaro approved for weight loss?
No. As of 2026-10-06 Mounjaro is approved for type 2 diabetes and cardiovascular risk reduction in high-risk adults with type 2 diabetes. Zepbound is the tirzepatide brand approved for weight management.
Is Mounjaro the same as Zepbound?
Both contain tirzepatide, but they are separate products with separate labels, indications and often different insurance coverage.
Can children take Mounjaro?
Since December 19, 2025 the label includes children and teens 10 and older with type 2 diabetes, with a lower maximum dose than adults. It is not approved for weight management at any age.
Does Mounjaro affect birth control pills?
It can. The label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase.
Official sources
References
- MOUNJARO (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- Drugs@FDA: Mounjaro, NDA 215866, approval history. U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
- Frias JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2107519 · PMID 34170647 · NCT03987919 (accessed October 7, 2026) Randomized trial
- Nicholls SJ, Pavo I, Bhatt DL, et al.. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2505928 · PMID 41406444 · NCT04255433 (accessed October 6, 2026) Randomized trial
- Mounjaro savings and resources. Eli Lilly and Company. (accessed October 7, 2026) Other
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.